In Phase II, for investigating the intravenous administration of GSK2586881 in patients with acute respiratory distress syndrome, the safety and efficacy were confirmed for its (well) toleration with a wide range of doses, and ACE2-mediated rapid transformation of Ang II to Ang 1–7, as well as tendency to reduce IL-6 levels [105,106]. Here, ANGPT1 is linked to acute respiratory distress syndrome.